A Case of Interstitial Pneumonitis Causedby Leflunomide

Leflunomide is a new disease modifying anti rheumatic drug (DMARD) for the treatment of active rheumatoid arthritis. Its mechanism of action differs from other DMARDs in that it inhibits the de novo pyrimidine synthesis by inhibiting dihydroorotate dehydrogenase and therefore prevents the proliferation of activated lymphocytes. As it has been prescribed worldwide, there is a great deal of much concerns regarding its potential adverse effects. Because leflunomide has an active metabolite with a long elimination half life of approximately 2 weeks, serious adverse reactions may occur even after the leflunomide treatment has been stopped. The profile of serious reactions includes liver dysfunction, hematological disorders, severe skin reactions and respiratory dysfunction. Respiratory dysfunctions with leflunomide therapy are very rare and its incidence is lower than that of methotrexate therapy. However, there are reports in Japan showing that 5 patients died of interstitial pneumonitis and another 11 patients developed serious lung complications associated with leflunomide. This suggests the possibility of fatal respiratory toxicity of leflunomide. There are no reports of interstitial pneumonitis associated with leflunomide in Korea. We report a case of a 62 year old woman who developed interstitial pneumonitis, which might have been induced by leflunomide during the treatment of rheumatoid arthritis. (Tuberc Respir Dis 2005; 58:83-88)

keywords: Leflunomide, Interstitial pneumonitis, Rheumatoid arthritis, Methotrexate

Reference

(1996) . Dihydroorotate dehydrogenase is a target for the biological effects of leflunomide.,

(2004) Japan deaths spark concerns over ar;thritis drug.,

(2002) Leflunomide(Arava) hematologic, hepatic and respiratory reactions,

(1994) Bronchiectasis:a late feature of severe rheumatoid arthritis,

(1996) p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. ,

(1997) Leflunomide and malononitr;ilamides,

(1998) A case of methotrexate-associated inter stitial pneumonitis in rheumatoid arthritis,

(.2002) Arthritis drug should be removed from market, says consumer group,

(2000) Methotrexate pneumonitis:review of the literature and histopathological findings in nine patients,

10.

(1998) Clinical experience with leflunomide in rheumatoid arthritis. ,

11.

(2004) A case of hypersensitivity pneumonitis caused by methotrexate,

12.

(1999) et al. Treatment of active rheumatoid arthritis with leflunomide compared to placebo and methotrexate. ,

13.

(1999) et al. Efficacy and safety of leflun� omide compared with placebo and sulphasalazine in active rheumatoid arthritis, multicenter trial. Lancet 1999

14.

(2001) Leflunomide: serious hepatic, blood, skin and respiratory reactions,

바로가기메뉴

Article Contents

Vol.58 No.1

A Case of Interstitial Pneumonitis Causedby Leflunomide

Abstract

Reference

Tuberculosis & Respiratory Diseases